Funding rounds
5 company funding rounds disclosed in the weekly RiseFinder box for Week 42 · 12 October 2026.
- Period
- Weekly
- Window
- 7d
- Rows
- 5
- Data through
- Week 42 · 12 October 2026
01/Weekly box
5 entries
01On its website, the company describes its work as “Finwave brings the power of Moore’s Law and scaling to RF GaN devices. Finwave’s patented approach for linearizing both power amplifiers (PAs) and low noise…”. Its SEC Form D filed on 2026-10-08 reports US$15,532,045 in securities sold, with a first sale date of 2026-08-25. The amount reflects the securities sales disclosed by the company in this offering at the filing date; it is separate from the offering's target amount and from measures of product traction.
SEC Form D
Open source ↗$15.5m
$15.5m of $21.2m target
On its website, the company describes its work as “Founded by a group of Carnegie Mellon alumni including a pediatric surgeon, PECA Labs is revolutionizing cardiovascular implantable devices with a polymer platform and a…”. Its SEC Form D filed on 2026-10-09 reports US$12,789,342 in securities sold, with a first sale date of 2026-09-30. The amount reflects the securities sales disclosed by the company in this offering at the filing date; it is separate from the offering's target amount and from measures of product traction.
SEC Form D
Open source ↗$12.8m
$12.8m of $21.5m target
On its website, the company describes its work as “ORBIT ELECTRONICS GROUP Delivering leading-edge operator interfaces that stand up to the most severe battlefield, shipboard and airborne conditions. Go to the Orbit Electronics Group…”. Its SEC Form D filed on 2026-10-07 reports US$4,075,000 in securities sold, with a first sale date of 2026-09-23. The amount reflects the securities sales disclosed by the company in this offering at the filing date; it is separate from the offering's target amount and from measures of product traction.
SEC Form D
Open source ↗$4.1m
$4.1m of $4.1m target
On its website, the company describes its work as “PreciseBreast® uses OncoIntelligence TM , our proprietary AI-platform, to combine AI-grade with key clinical factors to produce an OncoIntelligence Score TM . PreciseBreast®, clinically…”. Its SEC Form D filed on 2026-10-07 reports US$3,699,998 in securities sold, with a first sale date of 2026-09-23. The amount reflects the securities sales disclosed by the company in this offering at the filing date; it is separate from the offering's target amount and from measures of product traction.
SEC Form D
Open source ↗$3.7m
$3.7m of $3.7m target
On its website, the company describes its work as “The CI acceleration platform used by teams that ship fast Detect, quarantine, and eliminate flaky tests Any language, any test runner, any CI provider. →…”. Its SEC Form D filed on 2026-10-07 reports US$2,825,940 in securities sold, with a first sale date of 2026-09-24. The amount reflects the securities sales disclosed by the company in this offering at the filing date; it is separate from the offering's target amount and from measures of product traction.
SEC Form D
Open source ↗$2.8m
$2.8m of $6.8m target
This dated edition is generated from the reviewed RiseFinder export. Movement figures retain their original source, period and direction.
02/Get email updates
Join the list
Get early signals on the websites, apps, repositories and startups gaining momentum. Join the list for Risefinder email briefings.
By subscribing, you ask us to store your email and send Risefinder updates. You can unsubscribe at any time. Privacy.
Want a sample first? Read past daily emails.